Sharp Therapeutics (TSXV:SHRX) Total Operating Expense: C$7.67 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:SHRX Sharp Therapeutics Corp TSXV:SHRX
15 GF Score
Price C$0.91
View Full Analysis

What is Sharp Therapeutics Total Operating Expense?

Sharp Therapeutics TSXV:SHRX 15 Total Operating Expense is C$7.67 Mil as of Dec. 2025. GuruFocus rates TSXV:SHRX with a GF Score™ of 15/100.

Sharp Therapeutics's Total Operating Expense for the three months ended in Dec. 2025 was C$2.37 Mil. Sharp Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was C$7.67 Mil.

Sharp Therapeutics Total Operating Expense Related Terms

Sharp Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Sharp Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sharp Therapeutics Total Operating Expense Chart

Sharp Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Total Operating Expense
3.04 6.49 7.61

Sharp Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only 3.03 1.90 1.96 1.44 2.37
TSXV:SHRX
15GF Score
Sharp Therapeutics Corp TSXV:SHRX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sharp Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$7.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of C$7.67 Mil mean?
Sharp Therapeutics (TSXV:SHRX) has a Total Operating Expense of C$7.67 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Sharp Therapeutics and its competitors.
Is Sharp Therapeutics' Total Operating Expense too high?
Sharp Therapeutics' current Total Operating Expense is C$7.67 Mil. Overall, Sharp Therapeutics has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Total Operating Expense compare to VRTX and REGN?
Sharp Therapeutics' Total Operating Expense of C$7.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Sharp Therapeutics and its competitors. Sharp Therapeutics's current Total Operating Expense is C$7.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (TSXV:SHRX) has a current Total Operating Expense of C$7.67 Mil. The current Total Operating Expense is C$7.67 Mil. Sharp Therapeutics' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Sharp Therapeutics (TSXV:SHRX), the current Total Operating Expense is C$7.67 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sharp Therapeutics Business Description

Address 2403 Sidney Street, Suite 264, Pittsburgh, PA, USA, 15203
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
15GF Score

Get the complete analysis for TSXV:SHRX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.91
Price